07:06:03 EDT Mon 23 Sep 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Canada House Wellness Group Inc
Symbol C : CHV
Shares Issued 194,189,765
Close 2019-09-10 C$ 0.08
Recent Sedar Documents

Canada House arranges $14.58-million financing

2019-09-11 06:45 ET - News Release

Mr. Chris Churchill-Smith reports

CANADA HOUSE WELLNESS GROUP INC. BUILDS OFF SALES LICENSE, EXECUTES CONVERTIBLE SECURITY FUNDING AGREEMENT

Canada House Wellness Group Inc. has entered into a financing agreement for the issue of convertible securities for gross proceeds of up to $14,587,500 with an entity managed by the Lind Partners, a New York-based institutional fund manager. At the first closing, the company will issue a convertible security to the investor with a face value of $3,105,000.

"This investment from the Lind Partners is a strong validation of the fundamentals of our business and further accelerates our path to profitability," said Chris Churchill-Smith, chief executive officer, Canada House. "Along with our sales licence amendment which allows us to sell our own Abba Medix-branded cannabis to patients and consumers, this investment bolsters our balance sheet as we continue to transform our business."

"We were impressed by Canada House's plan for the organization and its mission of helping veterans with PTSD," said Jeffrey Easton, founder of the Lind Partners. "Canada House's leadership, structure and plans for vertical integration sets them up for success and we are excited to see where this investment will take them."

The first convertible security will have a term of 24 months and be convertible into common shares of the company at a fixed conversion price per share of eight cents, being the last closing price of the company's common shares on the Canadian Securities Exchange prior to execution of the convertible security financing agreement.

The $3,105,000 face value of the first convertible security comprises a principal amount of $2,587,500 and a prepaid interest amount of $517,500. The company is required to repay the principal amount of the first convertible security in 18 equal monthly payments commencing the seventh month after closing, except that the repayment amount will be reduced in any month by any amount converted by the investor into the company's common shares.

Prepaid interest will accrue monthly with the investor having the right to convert accrued interest into the company's common shares once accrued at a conversion price equal to the last closing market price of the shares on the exchange on the day prior to conversion. Upon receiving an accrued interest conversion notice from the investor, the company may elect to satisfy that conversion in cash.

Upon issuance of the first convertible security, the investor will also receive 16,171,875 warrants of the company, with each warrant entitling the investor to purchase one common share at an exercise price of 15 cents. The warrants expire 36 months from their date of issue, provided that if the volume-weighted average price of the company's common shares is at least 60 cents for 20 consecutive trading days, then the expiry date of the warrants may be accelerated by the company.

The company has the right to buy back the first convertible security and the prepaid interest at any time with no penalty. Should the company exercise its buyback right, the investor will have the right to convert 25 per cent of the outstanding principal amount and 100 per cent of the prepaid interest into the company's common shares.

The first convertible security is secured by a general security agreement from the company and certain of its subsidiaries.

Under the financing agreement, the company and the investor may agree for the investor to advance up to an additional $12-million in gross proceeds to the company in exchange for an increase of the first convertible security and the issuance of a second convertible security on the same terms as the first convertible security.

The closing of the investment is expected to occur on or about Sept. 13, 2019. Closing of the investment is subject to customary closing conditions.

About Canada House Wellness Group Inc.

Canada House Wellness is the parent company of: Abba Medix, a licensed producer in Pickering, Ont., that produces high-quality medical-grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider and patient to data that support treatment with medical cannabis.

Canada House Wellness's goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.